Y
Yi Yan Yang
Researcher at Agency for Science, Technology and Research
Publications - 374
Citations - 22011
Yi Yan Yang is an academic researcher from Agency for Science, Technology and Research. The author has contributed to research in topics: Micelle & Antimicrobial. The author has an hindex of 75, co-authored 358 publications receiving 19328 citations. Previous affiliations of Yi Yan Yang include National University of Singapore & Imperial College London.
Papers
More filters
Journal ArticleDOI
Fabrication and characterization of nanostructured and thermosensitive polymer membranes for wound healing and cell grafting
TL;DR: In this paper, the synthesis and characterization of membranes with various compositions are presented in detail, focusing on the effects of environmental temperature and membrane composition on surface hydrophilicity, cell attachment, and detachment.
Journal ArticleDOI
Phase behavior study of paclitaxel loaded amphiphilic copolymer in two solvents by dissipative particle dynamics simulations
TL;DR: In this article, the phase behavior of paclitaxel loaded PEO11-b-PLLA9 in water and N,N-Dimethylformamide was analyzed.
Journal ArticleDOI
Auto-catalyzed poly(ortho ester) microspheres: a study of their erosion and drug release mechanism.
TL;DR: Investigation of the degradation and protein release mechanisms of BSA-loaded microspheres made with auto-catalyzed poly(ortho esters) (POEs) of varying diol composition and molecular weights found constancy in molecular weight was similarly reflected in the glass transition temperature of the degrading micro Spheres.
Journal ArticleDOI
Galactose‐Functionalized Cationic Polycarbonate Diblock Copolymer for Targeted Gene Delivery to Hepatocytes
TL;DR: The galactose-functionalized cationic polycarbonate diblock copolymer has potential for use as a non-viral gene vector for the targeted delivery of therapeutic genes to hepatocytes in the treatment of liver diseases.
Journal ArticleDOI
Broad Spectrum Macromolecular Antimicrobials with Biofilm Disruption Capability and In Vivo Efficacy
Jeremy P. K. Tan,Daniel J. Coady,Haritz Sardon,Haritz Sardon,Alexander Y. Yuen,Shujun Gao,Shaun W. Lim,Zhen Chang Liang,Eddy W. P. Tan,Shrinivas Venkataraman,Amanda C. Engler,Mareva Fevre,Robert J. Ono,Yi Yan Yang,James L. Hedrick +14 more
TL;DR: The low cost of starting materials, ease of synthesis, nontoxicity, broad spectrum activity with fast killing kinetics, and in vivo antimicrobial activity make these macromolecular antimicrobials ideal candidates for prevention of sepsis and treatment of infections.